NRC

AI MemoPost-earnings T+3

NRC Health

As of 2026-07-31/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results show recurring-growth strength • 2026-07-28

Base target: $22 / p=50% prob

Biggest risk

GAAP net loss was $3.3 million, operating cash flow was only $1.4 million, and free cash flow was $0.1 million after approximately $2.9 million of adjustment-related cash payments. TRCV growth also exceeded reported revenue growth, leaving conversion and margin execution as key risks. [#SEC-8K-2026-07-28]

Invalidation

Break below $16 or thesis failure.

What would change my mind?

Q2 confirmed double-digit TRCV growth, positive adjusted profitability, and strong bookings, supporting the possibility of better second-half execution. The release also highlighted ongoing product innovation commercialization. [#SEC-8K-2026-07-28]

Research note

Recommendation

—

Confidence

medium

As of

2026-07-31

Base target

$22

p=50%

Bull target

$24

p=25%

Bear target

$16

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recurring-contract growth and product commercialization
Q2 confirmed double-digit TRCV growth, positive adjusted profitability, and strong bookings, supporting the possibility of better second-half execution.
The release also highlighted ongoing product innovation commercialization.

BearKey bullets

GAAP losses and adjustment-related cash payments may continue to obscure underlying performance.
Healthcare-organization demand and execution in the second half remain unverified.
Low analyst coverage and a loose peer set reduce valuation confidence.

WatchKey bullets

Q2 2026 results show recurring-growth strength

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $22 (p=50%)

Target spread vs base: +12% / -26%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $22 (p=50%)Bear Target: $16 (p=25%)

Commentary

News tone is mildly positive after the Q2 release, led by TRCV growth and bookings commentary, but the financial profile remains mixed because GAAP earnings and free cash flow were weak. No verified post-print analyst revisions were available, and social, options, short-interest, and employee data were not provided. The RankAlpha anchor was $18.91 on July 30; the live finance feed showed $19.11 intraday on July 31, without evidence attributing that move to earnings.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recurring-contract growth and product commercialization

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$22 / p=50% prob

Bear Target (Scenario probability)

$16 / p=25% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-28
Q2 2026 results show recurring-growth strength
NRC reported Q2 TRCV of $151.9 million, up 11% year over year, revenue up 4% to $35.4 million, adjusted net income of $6.9 million, and adjusted EBITDA of $9.4 million. Management also cited strong execution, product commercialization, and the strongest Governance Institute bookings in seven years. [#SEC-8K-2026-07-28]
Prob 100.00% • Move 4.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Recurring-contract growth and product commercialization
2027-07-31
Sustained TRCV growth and continued commercialization of product innovations could support a stronger second half, but the thesis remains dependent on converting recurring-value growth into revenue, margins, and cash flow. [#SEC-8K-2026-07-28]
Prob 60% • Move 12% • Priced-in 45%

Risks

GAAP losses and adjustment-related cash payments may continue to obscure underlying performance.
Healthcare-organization demand and execution in the second half remain unverified.
Low analyst coverage and a loose peer set reduce valuation confidence.
TRCV growth may not translate into equivalent revenue or margin expansion.
Weak cash conversion despite positive adjusted earnings.

Peers

Symbol	Summary
CLPT	Small-cap medtech reference with healthcare exposure, but its neuro-device model is not a close operating comparable to NRC's healthcare experience software and services.
AUNA	Small-cap healthcare-services reference with sector and size overlap; business mix and recurring-revenue profile differ materially from NRC.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

CLPT

Small-cap medtech reference with healthcare exposure, but its neuro-device model is not a close operating comparable to NRC's healthcare experience software and services.

AUNA

Small-cap healthcare-services reference with sector and size overlap; business mix and recurring-revenue profile differ materially from NRC.